pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›DUPIXENT
drug · antibody
save

DUPIXENT

updated 6mo ago
/ dew-PIL-oo-mab /
by $REGN REGENERON PHARMACEUTICALS, INC.🔗 ChEMBL
community read0 votes

🐶 often sniffed alongside

top 7
  • drugdupilumab126 co-mentions · 33 sources
  • tagApproval124 co-mentions · 31 sources
  • tagPulmonology1 co-mentions · 1 sources
  • tagAsthma1 co-mentions · 1 sources
  • tagPDUFA1 co-mentions · 1 sources
  • tagDermatology1 co-mentions · 1 sources
  • companyBrigham and Women's Hospital1 co-mentions · 1 sources

Antibody drug with a maximum clinical stage of Approval (across all indications), with 8 approved and 30 investigational indications.

targets

Interleukin-4 receptor subunit alpha

all catalysts(0)

nothing on the calendar yet

Trials studying DUPIXENT

  • —A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving Dupilumabactive not recruitingn=303
  • phase4Ethnic Differences in Mechanisms of Action of Dupilumabrecruitingn=30
  • phase3A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistaminesactive not recruitingn=409
  • phase1Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy Participantscompletedn=40
  • phase3Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)recruitingn=284
  • phase1An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitisactive not recruitingn=86
  • phase3A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthmarecruitingn=150
  • —Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Studycompletedn=110

News(10)

  • Sanofi gains FDA clearance for Gaucher disease pill
    The approval culminates a winding development journey for Infilbray, and provides Sanofi with a new source of income ahead of Dupixent’s looming patent expiration.
    biopharma_dive · 3h ago
  • With FDA nod, Regeneron brings an RNAi drug to autoimmune disease
    The product of a collaboration with Alnylam, Livsayis is now Regeneron’s first marketed RNAi drug and will compete against established medicines from AstraZeneca and Argenx.
    biopharma_dive · 5h ago
  • Seawolf surfaces with $100M, $1.2B Sanofi pact for redosable DNA medicines
    Backed by Novartis’ venture arm, Eli Lilly and CRISPR Therapeutics, Seawolf is advancing its nonviral DNA delivery platform while inking a pact with Sanofi.
    biospace · 3d ago
  • Regeneron’s POTS antibody curbs heart rate spikes, teeing up Phase 3 trial
    Regeneron’s mid-stage success in postural orthostatic tachycardia syndrome has the company gearing up to launch a Phase 3 study in the first half of 2027.
    biospace · 6d ago
  • STAT+: Pharmalittle: We’re reading about India’s new manufacturing rules, clinical trials in China, and more
    India proposed rules requiring regulators to immediately suspend manufacturing licenses for drugs that fail quality standards in government testing
    stat · 14d ago
  • Sanofi stops development of Nurix-partnered immune drug
    The decision sparked a sell-off in Nurix shares as well as analyst debate about the prospects of drugs designed to degrade a tough-to-reach protein called STAT6.
    biopharma_dive · 15d ago
  • Sanofi’s axing of Nurix STAT6 program ‘not a target-related issue’
    Sanofi has discontinued an early-stage STAT6 degrader program licensed from Nurix Therapeutics, a decision analysts say is related to the asset itself or Sanofi’s strategic reprioritization rather…
    biospace · 15d ago
  • STAT+: Ultragenyx cuts staff after another study fails
    Ultragenyx announced that it's laying off about 20% of its staff as it ends development of two rare disease drugs.
    stat · 15d ago
  • STAT+: Pharmalittle: We’re reading about CVS plans to split up, FDA inspections in India and China and more
    The Trump administration will survey key components of pharmaceutical production in order to identify domestic supply chain vulnerabilities.
    stat · 15d ago
  • STAT+: Former Madrigal Pharmaceuticals executive alleges coverup of safety issues tied to its drug
    A top former executive at Madrigal Pharmaceuticals has filed a lawsuit in federal court alleging a coverup of drug safety issues.
    stat · 15d ago
view all news mentions →
brand
DUPIXENT
trade names
Dupixent, Regn668, sar231893
generic
DUPILUMAB
MOA
12.1 Mechanism of Action Dupilumab is a human monoclonal IgG4 antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling by specifically binding to the IL-4Rα subunit shared by the IL-4 and IL-13 receptor complexes. Dupilumab inhibits IL-4 signaling via the Type I receptor and both IL-4 and IL-13 signaling through the Type II receptor. Inflammation driven by IL-4 and IL-13 is an important component in the pathogenesis of asthma, AD, CRSwNP, EoE, PN, COPD, CSU, BP, and AFRS. Multiple cell types that express IL-4Rα (e.g., mast cells, basophils, eosinophils, macrophages, lymphocytes, epithelial cells, goblet cells) and inflammatory mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines, chemokines) are involved in inflammation. Blocking IL-4Rα with dupilumab inhibits IL-4 and IL-13 cytokine-induced inflammatory responses, including the release of proinflammatory cytokines, chemokines, nitric oxide, and IgE. The mechanism of dupilumab action has not been definitively established.
indication
1 INDICATIONS AND USAGE DUPIXENT is an interleukin-4 receptor alpha antagonist indicated: Atopic Dermatitis for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. ( 1.1 ) Asthma as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. ( 1.2 ) Limitations of Use: Not for the relief of acute bronchospasm or status asthmaticus. ( 1.2 ) Chronic Rhinosinusitis with Nasal Polyps as an add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.3 ) Eosinophilic Esophagitis for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE). ( 1.4 ) Prurigo Nodularis for the treatment of adult patients with prurigo nodularis (PN). ( 1.5 ) Chronic Obstructive Pulmonary Disease as an add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.6 ) Limitations of Use: Not for the relief of acute bronchospasm. ( 1.6 ) Chronic Spontaneous Urticaria for the treatment of adult and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. ( 1.7 ) Limitations of Use: Not indicated for other forms of urticaria. ( 1.7 ) Bullous Pemphigoid for the treatment of adult patients with bullous pemphigoid (BP). ( 1.8 ) Allergic Fungal Rhinosinusitis for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) who h
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?